Physician profile
Michael J Swartz
NPI 1225174402
$413.36
in general payments reported to CMS, 2019-2025
15 companies · $69.38 in 2025
The $69.38 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $51.19 · 2022: $23.82 · 2023: $27.59 · 2024: $26.11 · 2025: $69.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $70.03 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $59.54 | 2019-2020 | |
| Pfizer INC. | $53.50 | 2025 | |
| Tesaro, INC. | $34.01 | 2019 | |
| Celgene Corporation | $27.66 | 2019 | |
| Siemens Medical Solutions USA, INC. | $27.59 | 2023 | Truebeam |
| Elekta, INC. | $23.82 | 2022 | |
| Taiho Oncology, INC. | $17.45 | 2019 | |
| Amgen INC. | $16.24 | 2019 | |
| Gilead Sciences, INC. | $15.88 | 2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $15.62 | 2019 | |
| Janssen Biotech, INC. | $15.60 | 2019 | |
| Seagen INC. | $13.52 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $11.47 | 2019 | |
| Incyte Corporation | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Swartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.